English
Since the development of CRISPR–Cas as a tool for targeted genome manipulation in 2012, genome editing has revolutionized basic and translational research around the globe1. The technology and its potential in bio-innovation were recently highlighted with the approval of the first CRISPR–Cas-based gene therapies for sickle cell anemia and β-thalassemia in humans. However, genome editing is currently underexplored in Africa, where it could be transformative in addressing key challenges in major sectors (including agriculture, public health and medicine).